131 related articles for article (PubMed ID: 31202437)
1. CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.
Dankner M; Ouellet V; Communal L; Schmitt E; Perkins D; Annis MG; Barrès V; Caron C; Mes-Masson AM; Saad F; Siegel PM;
Am J Pathol; 2019 Jul; 189(7):1451-1461. PubMed ID: 31202437
[TBL] [Abstract][Full Text] [Related]
2. CCN3 promotes prostate cancer bone metastasis by modulating the tumor-bone microenvironment through RANKL-dependent pathway.
Chen PC; Cheng HC; Tang CH
Carcinogenesis; 2013 Jul; 34(7):1669-79. PubMed ID: 23536580
[TBL] [Abstract][Full Text] [Related]
3. Prostate cancer-secreted CCN3 uses the GSK3β and β-catenin pathways to enhance osteogenic factor levels in osteoblasts.
Chen PC; Liu SC; Lin TH; Lin LW; Wu HC; Tai HC; Wang SW; Tang CH
Environ Toxicol; 2021 Mar; 36(3):425-432. PubMed ID: 33107671
[TBL] [Abstract][Full Text] [Related]
4. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
[TBL] [Abstract][Full Text] [Related]
5. CCN3 impairs osteoblast and stimulates osteoclast differentiation to favor breast cancer metastasis to bone.
Ouellet V; Tiedemann K; Mourskaia A; Fong JE; Tran-Thanh D; Amir E; Clemons M; Perbal B; Komarova SV; Siegel PM
Am J Pathol; 2011 May; 178(5):2377-88. PubMed ID: 21514448
[TBL] [Abstract][Full Text] [Related]
6. A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer.
Ylitalo EB; Thysell E; Landfors M; Brattsand M; Jernberg E; Crnalic S; Widmark A; Hultdin M; Bergh A; Degerman S; Wikström P
Clin Epigenetics; 2021 Jun; 13(1):133. PubMed ID: 34193246
[TBL] [Abstract][Full Text] [Related]
7. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.
Kang HY; Huang HY; Hsieh CY; Li CF; Shyr CR; Tsai MY; Chang C; Chuang YC; Huang KE
J Bone Miner Res; 2009 Jul; 24(7):1180-93. PubMed ID: 19257827
[TBL] [Abstract][Full Text] [Related]
8. Polycomb-Mediated Disruption of an Androgen Receptor Feedback Loop Drives Castration-Resistant Prostate Cancer.
Fong KW; Zhao JC; Kim J; Li S; Yang YA; Song B; Rittie L; Hu M; Yang X; Perbal B; Yu J
Cancer Res; 2017 Jan; 77(2):412-422. PubMed ID: 27815387
[TBL] [Abstract][Full Text] [Related]
9. CCN3/NOV gene expression in human prostate cancer is directly suppressed by the androgen receptor.
Wu L; Runkle C; Jin HJ; Yu J; Li J; Yang X; Kuzel T; Lee C; Yu J
Oncogene; 2014 Jan; 33(4):504-13. PubMed ID: 23318417
[TBL] [Abstract][Full Text] [Related]
10. Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.
Jernberg E; Thysell E; Bovinder Ylitalo E; Rudolfsson S; Crnalic S; Widmark A; Bergh A; Wikström P
PLoS One; 2013; 8(11):e77407. PubMed ID: 24244276
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer-derived CCN3 induces M2 macrophage infiltration and contributes to angiogenesis in prostate cancer microenvironment.
Chen PC; Cheng HC; Wang J; Wang SW; Tai HC; Lin CW; Tang CH
Oncotarget; 2014 Mar; 5(6):1595-608. PubMed ID: 24721786
[TBL] [Abstract][Full Text] [Related]
12. CCN3 increases cell motility and MMP-13 expression in human chondrosarcoma through integrin-dependent pathway.
Tzeng HE; Chen JC; Tsai CH; Kuo CC; Hsu HC; Hwang WL; Fong YC; Tang CH
J Cell Physiol; 2011 Dec; 226(12):3181-9. PubMed ID: 21344378
[TBL] [Abstract][Full Text] [Related]
13. Paracrine effects of CCN3 from non-cancerous hepatic cells increase signaling and progression of hepatocellular carcinoma.
Li W; Liao X; Ning P; Cao Y; Zhang M; Bu Y; Lv J; Jia Q
BMC Cancer; 2019 Apr; 19(1):395. PubMed ID: 31029128
[TBL] [Abstract][Full Text] [Related]
14. CCN3 increases cell motility and ICAM-1 expression in prostate cancer cells.
Chen PC; Lin TH; Cheng HC; Tang CH
Carcinogenesis; 2012 Apr; 33(4):937-45. PubMed ID: 22345292
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 is a selective modifier of androgen-dependent signaling and androgen receptor function.
Comstock CES; Augello MA; Schiewer MJ; Karch J; Burd CJ; Ertel A; Knudsen ES; Jessen WJ; Aronow BJ; Knudsen KE
J Biol Chem; 2011 Mar; 286(10):8117-8127. PubMed ID: 21212260
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer osteomimicry and its role in bone specific metastasis; an integrative, systematic review of preclinical evidence.
Awolaran O; Brooks SA; Lavender V
Breast; 2016 Dec; 30():156-171. PubMed ID: 27750106
[TBL] [Abstract][Full Text] [Related]
17. High expression of small nucleolar RNA host gene 3 predicts poor prognosis and promotes bone metastasis in prostate cancer by activating transforming growth factor-beta signaling.
Xi X; Hu Z; Wu Q; Hu K; Cao Z; Zhou J; Liao J; Zhang Z; Hu Y; Zhong X; Bao Y
Bioengineered; 2022 Jan; 13(1):1895-1907. PubMed ID: 35030969
[TBL] [Abstract][Full Text] [Related]
18. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
[TBL] [Abstract][Full Text] [Related]
19. Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.
Hörnberg E; Ylitalo EB; Crnalic S; Antti H; Stattin P; Widmark A; Bergh A; Wikström P
PLoS One; 2011 Apr; 6(4):e19059. PubMed ID: 21552559
[TBL] [Abstract][Full Text] [Related]
20. A novel prostate cancer therapeutic strategy using icaritin-activated arylhydrocarbon-receptor to co-target androgen receptor and its splice variants.
Sun F; Indran IR; Zhang ZW; Tan MH; Li Y; Lim ZL; Hua R; Yang C; Soon FF; Li J; Xu HE; Cheung E; Yong EL
Carcinogenesis; 2015 Jul; 36(7):757-68. PubMed ID: 25908644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
